Evidence map›Paper›PMID 42169689›Full record

ArticleOpen forum infectious diseases2026

Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis.

Jennifer H Ku, Lei Qian, Lina S Sy, Bradley K Ackerson, Emily Rayens, Yi Luo, Sijia Qiu, Lanfang Xu, Gina S Lee, Punam P Modha and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jennifer H KuCenter for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.ORCID https://orcid.org/0000-0001-9469-5875
Lei QianDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0001-8001-3992
Lina S SyDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-2762-9266
Bradley K AckersonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-0816-7345
Emily RayensDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-3369-3475
Yi LuoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0001-8990-2470
Sijia QiuDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-4828-3180
Lanfang XuMedhealth Analytics Inc., Sugar Land, Texas, USA.
Gina S LeeDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-7554-9116
Punam P ModhaDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0008-2274-1543
Cheyne F HokeDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Cynthia JoeDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Britta I AmundsenDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.ORCID https://orcid.org/0009-0007-6301-1611
Jean-Yves PirçonGSK, Wavre, Belgium.ORCID https://orcid.org/0009-0003-1542-3292
Lauriane HarringtonGSK, Wavre, Belgium.
Nicolas LecrenierGSK, Wavre, Belgium.
David SingerGSK, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-8008-8003
Elizabeth M LaGSK, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-5652-8961
Andrew G AllmonGSK, Durham, North Carolina, USA.
Dominique LuytsGSK, Wavre, Belgium.
Hung-Fu TsengDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a test-negative design, we estimated within-season vaccine effectiveness (VE) of adjuvanted RSVPreF3 against laboratory-confirmed respiratory syncytial virus (RSV)-lower respiratory tract disease-associated hospitalizations in adults ≥60 years during Dec2023-Feb2025. Results showed 82.3% overall VE and 81.0%-92.1% VE across subgroups, including those at increased risk of severe RSV disease.

Indexed as

adjuvanted RSVPreF3lower respiratory tract diseaserespiratory syncytial virustest-negative designvaccine effectiveness

Identifiers

PMID42169689
PMCPMC13188842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.